A cytoskeleton regulator AVIL drives tumorigenesis in glioblastoma

Glioblastoma is a deadly cancer, with no effective therapies. Better understanding and identification of selective targets are urgently needed. We found that advillin (AVIL) is overexpressed in all the glioblastomas we tested including glioblastoma stem/initiating cells, but hardly detectable in non-neoplastic astrocytes, neural stem cells or normal brain. Glioma patients with increased AVIL expression have a worse prognosis. Silencing AVIL nearly eradicated glioblastoma cells in culture, and dramatically inhibited in vivo xenografts in mice, but had no effect on normal control cells. Conversely, overexpressing AVIL promoted cell proliferation and migration, enabled fibroblasts to escape contact inhibition, and transformed immortalized astrocytes, supporting AVIL being a bona fide oncogene. We provide evidence that the tumorigenic effect of AVIL is partly mediated by FOXM1, which regulates LIN28B, whose expression also correlates with clinical prognosis. AVIL regulates the cytoskeleton through modulating F-actin, while mutants disrupting F-actin binding are defective in its tumorigenic capabilities.


Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: -Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability The Raw and processed RNA-Sequencing data from this study have been submitted to the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE64032. Microarray data for this study has also been deposited onto the GEO database, GSE95164. The other data that support the findings of this study are available from the corresponding author upon reasonable request.

nature research | reporting summary
April 2020 Field-specific reporting Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative.

Sample size
Sample size for each experiment is indicated in the legend or methods. No statistical tests were used to pre-determine sample size. Sample size was chosen based on previous experiments and comparable studies in literature, which is most optimal to generate statistically significant results.
Data exclusions No data was excluded for analysis.

Replication
Each animal experiment presented in the paper was repeated in multiple animals (>= 6 per experiment) , and all results in the paper are drawn from the analysis of multiple animals. For other experiments, all attempts at replication were successful. The number of replications was stated in the figure legends of Methods.
Randomization For animal experiments, animals were assigned randomly to experimental and control groups. Cells were all plated at the same time and wells were randomly selected for different treatment with stimuli or inhibitors.

Blinding
Blinding was not applicable as it was not a randomized clinical trial.

Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Authentication
None of the cell lines have been authenticated.

Mycoplasma contamination
Cell lines were not tested for mycoplasma contamination but no indication of contamination was observed.
Commonly misidentified lines (See ICLAC register) No commonly misidentified cell lines were used.

nature research | reporting summary
April 2020 Animals and other organisms Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Wild animals
No wild animals were used in this study.
Field-collected samples No field-collected samples were used in this study.

Ethics oversight
The mouse work was performed under the study protocol 4234 as approved by the University of Virginia Institutional Animal Care and Use Committee.
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Magnetic resonance imaging Sequence & imaging parameters T1-weighted serial coronal images of each brain were acquired at 1 mm intervals with a 5 x 5 mm field, and a 256 x 256 pixel resolution.

Area of acquisition
Whole brain was scanned.
Diffusion MRI Used Not used Preprocessing Preprocessing software ImageJ version 1.52a was used for measuring tumor volumes. All brain sections for each mouse was imported as an image sequence.

Normalization
All images from all mice were adjusted for equal brightness and contrast.

Normalization template
No specific template was used.
Noise and artifact removal A luminosity histogram was first generated for a selected area of the left cerebrum that was grossly tumor-free. This served as an internal control for background.

Volume censoring
No volume censoring was done.

Statistical modeling & inference
Model type and settings No statistical modeling was done with these images.

Effect(s) tested
Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.
Specify type of analysis: Whole brain ROI-based Both Statistic type for inference (See Eklund et al. 2016) Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.

Correction
Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).